The hottest topics of the global biomedical industry include immunotherapy, liquid biopsy, as well as the Next Generation Sequencing Technology (NGS), and companion diagnostics. Many experts and scholars believe that NGS will replace the traditional Sanger sequencing, and become the mainstream of the genetic testing market due to its advantage of high quality and low price. Is it really so? How can Taiwan assemble its domestic resources and promote the excellent R & D capabilities to the global market? It is with a great honor to interview the director of scientific research of Libo Health & Medical Corporation (Libo Health), Dr. Chien-hsiang Tang (唐建翔), who will share his recommendations with us through his own observations of the industry. How should Genetic Testing be going? Just follow the Medical demands.